✦ LIBER ✦

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

✍ Scribed by Ronald Emkey; Pierre D. Delmas; Michael Bolognese; Joao Lindolfo C. Borges; Felicia Cosman; Sergio Ragi-Eis; Christopher Recknor; Cristiano A. Zerbini; Colin Neate; Farhad Sedarati; Solomon Epstein

Book ID: 113543967
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 145 KB
Volume: 31
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2009.04.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Compliance, persistence and patient sati

Compliance, persistence and patient satisfaction in 150 mg once-monthly oral ibandronate treated patients with postmenopausal osteoporosis — A non-interventional study

✍ H. Börst; D. Felsenberg; J. Glaab; O. Bock 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Efficacy and safety of a once-yearly i.v

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi